Titan Securities FY26 profit rises, CFO resigns
Titan Securities reported a consolidated net profit of ₹1,245.57 lakh for FY26, up from ₹1,047.36 lakh in FY25, despite a decline in revenue. CFO Darshana Santoshi resigned effective May 30, 2026, and the Board appointed a scrutinizer for the upcoming AGM.
*this image is generated using AI for illustrative purposes only.
Titan Securities reported a consolidated net profit of ₹1,245.57 lakh for the financial year ended March 31, 2026, an increase from ₹1,047.36 lakh in the previous year. The Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a meeting held on May 30, 2026. The statutory auditors, M/s. Goyal Nagpal & Co., issued an audit report with an unmodified opinion on the results.
The Board accepted the resignation of Mrs. Darshana Santoshi from the position of Chief Financial Officer (KMP) effective from the close of business hours on May 30, 2026, due to personal reasons. Additionally, the Board appointed Mr. Pankaj Kumar Gupta, a Practicing Company Secretary, as the scrutinizer to conduct the voting process for the 34th Annual General Meeting scheduled for 2026.
Financial Performance
The company's total revenue from operations for the year ended March 31, 2026, stood at ₹596.32 lakh on a consolidated basis, down from ₹1,042.23 lakh in the previous year. For the quarter ended March 31, 2026, total revenue from operations was ₹280.85 lakh. The profit before tax for the year was ₹113.56 lakh, while the profit after tax was ₹83.55 lakh on a standalone basis.
Consolidated Results
The consolidated results include the financial performance of associate companies, Titan Biotech Limited and Peptech Biosciences Limited. The share in profit of associates for the year amounted to ₹1,162.02 lakh, significantly contributing to the total consolidated profit. The total comprehensive income for the period was ₹1,242.40 lakh for the year ended March 31, 2026.
Key Financial Metrics (Consolidated)
| Metric | Year Ended 31.03.2026 (₹ in Lakhs) | Year Ended 31.03.2025 (₹ in Lakhs) |
|---|---|---|
| Total Revenue from Operations | 596.32 | 1,042.23 |
| Total Expenses | 482.76 | 895.25 |
| Profit for the Period | 1,245.57 | 1,047.36 |
| Earnings Per Share (Basic) | 4.98 | 4.19 |
The management noted a change in the measurement basis of the investment in Peptech Biosciences Ltd. from fair value to cost, following a reassessment of strategic intent. The financial statements were prepared in compliance with Indian Accounting Standards (Ind AS).
Historical Stock Returns for Titan Securities
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.41% | -2.06% | -5.13% | +11.31% | +29.59% | +323.60% |
How will the sudden resignation of the CFO impact Titan Securities' strategic financial planning and reporting stability in the coming quarters?
What is the strategic rationale behind shifting the measurement basis of the Peptech Biosciences investment from fair value to cost, and how will this affect future earnings volatility?
Given the significant reliance on associate companies for consolidated profits, does Titan Securities plan to diversify its revenue streams to reduce dependency on Titan Biotech and Peptech Biosciences?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
